

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

JUL 27 2001

PATENT &amp; TRADEMARK OFFICE

Sheet **1** of **1**

Attorney Docket No.

**98,385-I****Hauptmann et al.,****1646**

| Examiner Initials* | Cited Patent Document No. <sup>1</sup> | U.S. Patent Document Number | Kind Code <sup>2</sup><br>(if known) | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YYYY | Pages, Columns, Lines Where Relevant Passages or Figures Appear |   |
|--------------------|--|-----------------------------|--------------------------------------|---|--|---|---|
|                    |  |                             |                                      |   |  | Change Log  | 9 |
| EWA                | 1                                      | <b>4,289,690</b>            |                                      | Pestka et al.                                   | Sept. 15, 1981                                   |   |   |
|                    | 2                                      | <b>4,560,649</b>            |                                      | Saxena et al.                                   | Dec. 24, 1985                                    |   |   |
|                    | 3                                      | <b>4,578,335</b>            |                                      | Urdal et al.                                    | Mar. 25, 1986                                    |   |   |
|                    | 4                                      | <b>4,609,546</b>            |                                      | Hiratani  | Sept. 2, 1986                                    |   |   |
|                    | 5                                      | <b>4,789,658</b>            |                                      | Yoshimoto et al.                                | Dec. 6, 1988                                     |   |   |
|                    | 6                                      | <b>4,902,502</b>            |                                      | Nitecki et al.                                  | Feb. 20, 1990                                    |   |   |
|                    | 7                                      | <b>4,904,584</b>            |                                      | Shaw  | Feb. 27, 1990                                    |   |   |
|                    | 8                                      | <b>4,931,544</b>            |                                      | Katre et al.                                    | Jun. 5, 1990                                     |   |   |
|                    | 9                                      | <b>4,935,233</b>            |                                      | Bell et al.                                     | Jun. 19, 1990                                    |   |   |
|                    | 10                                     | <b>4,966,888</b>            |                                      | Saxena et al.                                   | Oct. 30, 1990                                    |   |   |
|                    | 11                                     | <b>5,089,261</b>            |                                      | Nitecki et al.                                  | Feb. 18, 1992                                    |   |   |
|                    | 12                                     | <b>5,116,964</b>            |                                      | Capon et al.                                    | May 26, 1992                                     |   |   |
|                    | 13                                     | <b>5,136,021</b>            |                                      | Dembinski et al.                                | Aug. 4, 1992                                     |   |   |
|                    | 14                                     | <b>5,153,265</b>            |                                      | Shadle et al.                                   | Oct. 6, 1992                                     |   |   |
|                    | 15                                     | <b>5,162,430</b>            |                                      | Rhee et al.                                     | 5,162,430  |   |   |
|                    | 16                                     | <b>5,214,131</b>            |                                      | Sano et al.                                     | May 25, 1993                                     |   |   |
|                    | 17                                     | <b>5,252,714</b>            |                                      | Harris et al.                                   | Oct. 12, 1993                                    |   |   |
|                    | 18                                     | <b>5,344,915</b>            |                                      | LeMaire et al.                                  | Sep. 6, 1994                                     |   |   |
|                    | 19                                     | <b>5,359,037</b>            |                                      | Wallach et al.                                  | Oct. 25, 1994                                    |   |   |
|                    | 20                                     | <b>5,382,657</b>            |                                      | Karasiewicz et al.                              | Jan. 17, 1995                                    |   |   |
|                    | 21                                     | <b>5,395,760</b>            |                                      | Smith et al.                                    | Mar. 7, 1995                                     |   |   |
|                    | 22                                     | <b>5,478,925</b>            |                                      | Wallach et al.                                  | Dec. 26, 1995                                    |   |   |
|                    | 23                                     | <b>5,512,544</b>            |                                      | Wallach et al.                                  | Apr. 30, 1996                                    |   |   |
|                    | 24                                     | <b>5,605,690</b>            |                                      | Jacobs et al.                                   | Feb. 25, 1997                                    |   |   |
| ✓                  | 25                                     | <b>5,610,279</b>            |                                      | Brockhaus et al.                                | Mar. 11, 1997                                    |   |   |

*Clear B.O'Han**1/21/03*

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English translation is attached.

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

of

98,385-I



Application No.

09/898,234

Filing Date:

7-3-01

First Named Inventor

Hauptmann et al.,

Group Art Unit

Examiner Name

JUL 31 2001

CONT'D

D

**U.S. PATENT DOCUMENTS**

| Examiner Initials* | Cite No. <sup>1</sup> | U.S. Patent Document |                                   | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YYYY | Pages, Columns, Lines Where Relevant Passages or Figures Appear |
|--------------------|-----------------------|----------------------|-----------------------------------|---|--|---|
|                    |                       | Number               | Kind Code <sup>2</sup> (if known) |   |  |   |
| EPA                | 26                    | 5,633,145            |                                   | Feldmann et al.                                 | May 27, 1997                                     |   |
|                    | 27                    | 5,695,953            |                                   | Wallach et al.                                  | Dec. 9, 1997                                     |   |
|                    | 28                    | 5,712,155            |                                   | Smith et al.                                    | Jan. 27, 1998                                    |   |
|                    | 29                    | 5,808,029            |                                   | Brockhaus et al.                                | Sep. 15, 1998                                    |   |
|                    | 30                    | 5,811,261            |                                   | Wallach et al.                                  | Sep. 22, 1998                                    |   |
|                    | 31                    | 5,843,791            |                                   | Hauptmann et al.                                | Dec. 1, 1998                                     |   |
| ✓                  | 32                    | 5,863,786            |                                   | Feldmann et al.                                 | Jan. 26, 1999                                    |   |

**FOREIGN PATENT DOCUMENTS**

| Examiner Initials* | Cite No. <sup>1</sup> | Foreign Patent Document |                                   | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YYYY | Pages, Columns, Lines Where Relevant Passages or Figures Appear | T <sup>6</sup> |
|--------------------|-----------------------|-------------------------|-----------------------------------|---|--|---|----------------|
|                    |                       | Number <sup>4</sup>     | Kind Code <sup>5</sup> (if known) |   |  |   |                |
| EPA                | 33                    | DE03910323A1            |                                   |   |  |   |                |
|                    | 34                    | DE03913101.7            |                                   |   |  |   |                |
| EPA                | 35                    | DE0920282.8             |                                   |   |  |   |                |
|                    | 36                    | EP0154316A2             |                                   |   |  |   |                |
|                    | 37                    | EP0154316B1             |                                   |   |  |   |                |
|                    | 38                    | EP0162699               |                                   |   |  |   |                |
|                    | 39                    | EP0225579A3             |                                   |   |  |   |                |
|                    | 40                    | EP0247860A2             |                                   |   |  |   |                |
|                    | 41                    | EP0259863A2             |                                   |   |  |   |                |
|                    | 42                    | EP0308378               |                                   |   |  |   |                |
|                    | 43                    | EP0334165A2             |                                   |   |  |   |                |
| ✓                  | 44                    | EP0393438A2             |                                   |   |  |   |                |

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC. 20231

|       |   |                      |                   |
|-------|---|----------------------|-------------------|
|       |   | Complete if Known    |                   |
|       |   | Application No.      | 09/898,234        |
|       |   | Filing Date:         | 7-3-01            |
|       |   | First Named Inventor | Hauptmann et al.. |
|       |   | Group Art Unit       |                   |
|       |   | Examiner Name        |                   |
| Sheet | 9 | Attorney Docket No.  | 98,385-I          |

**FOREIGN PATENT DOCUMENTS**

| Examiner Initials* | Cite No. <sup>1</sup> | Foreign Patent Document |                                      | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document<br>MM-DD-YYYY | Pages, Columns, Lines Where Relevant Passages or Figures Appear | T <sup>6</sup> |
|--------------------|-----------------------|-------------------------|--------------------------------------|---|---|---|----------------|
|                    |                       | Number <sup>4</sup>     | Kind Code <sup>5</sup><br>(if known) |   |   |   |                |
| EPA                | 45                    | EP0398327A1             |                                      |   |   |   |                |
|                    | 46                    | EP0412486               |                                      |   |   |   |                |
|                    | 47                    | EP0417563A2             |                                      |   |   |   |                |
|                    | 48                    | EP0418014A1             |                                      |   |   |   |                |
|                    | 49                    | EP0422339               |                                      |   |   |   |                |
|                    | 50                    | EP0433900               |                                      |   |   |   |                |
|                    | 51                    | EP0512528A2             |                                      |   |   |   |                |
|                    | 52                    | EP0526905A2             |                                      |   |   |   |                |
|                    | 53                    | GB2218101               |                                      |   |   |   |                |
|                    | 54                    | GB2246569A              |                                      |   |   |   |                |
|                    | 55                    | WO90/13575              |                                      |   |   |   |                |
|                    | 56                    | WO91/03553              |                                      |   |   |   |                |
|                    | 57                    | WO92/01002              |                                      |   |   |   |                |
|                    | 58                    | WO92/07076              |                                      |   |   |   |                |
|                    | 59                    | WO92/13095              |                                      |   |   |   |                |
|                    | 60                    | WO92/15682              |                                      |   |   |   |                |
|                    | 61                    | WO92/16221              |                                      |   |   |   |                |
|                    | 62                    | WO92/01474              |                                      |   |   |   |                |
| ▼                  | 63                    | WO94/06476              |                                      |   |   |   |                |

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC. 20231

|                      |                   |
|----------------------|-------------------|
| Application No.      | 09/898,234        |
| Filing Date:         | 7-3-01            |
| First Named Inventor | Hauptmann et al., |
| Group Art Unit       |                   |
| Examiner Name        |                   |
| Attorney Docket No.  | 98,385-I          |

JULY 3 2001  
PATENT & TRADEMARK OFFICE

Sheet

4

of

9

(use as many sheets as necessary)

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc).



|    |   |
|----|---|
| 64 | Anderson et al., "Quantitative Filter Hybridisation," <i>Nucleic Acid Hybridization: A Practical Approach</i> pp. 73-111 (Hawes et al., eds., 1985).  |
| 65 | Aggarwal et al., "Characterization of receptors for human tumour necrosis factor and their regulation by gamma-interferon," <i>Nature</i> 318:665-67 (1985).  |
| 66 | Baglioni et al., "Binding of human tumor necrosis factor to high affinity receptors on HeLa and lymphoblastoid cells sensitive to growth inhibition," <i>J. Biol. Chem.</i> 260:13395-97 (1985).                                      |
| 67 | Bakouche et al., "Plasma membrane-associated tumor necrosis factor. A non-integral membrane protein possibly bound to its own receptor," <i>J. Immunol.</i> 140:1142-47 (1988).   |
| 68 | Beutler et al., "The Biology of Cachectin/TNF-A Primary Mediator of the Host Response", <i>Ann. Rev. Immunol.</i> 1989, 7:625-55  |
| 69 | Binkert et al., "Cloning, sequence analysis and expression of a cDNA encoding a novel insulin-like growth factor binding protein (IGFBP-2)," <i>EMBO J.</i> 8:2497-502 (1989).  |
| 70 | Bowie et al., "Deciphering the message in protein sequences: tolerance to amino acid substitutions," <i>Science</i> 247:1306-10 (1990).   |
| 71 | Brennan et al., "Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis," <i>Lancet</i> 2:244-47 (1989).   |
| 72 | Brockhaus, M. et al., <i>Proc. Natl. Acad. Sci. USA</i> 87:3127-3131 (1990)   |
| 73 | Capaldi et al., "Changes in order of migration of polypeptides in complex III and cytochrome C oxidase under different conditions of SDS polyacrylamide gel electrophoresis," <i>Biochem. Biophys. Res. Commun.</i> 74:425-33 (1977). |
| 74 | Colletti et al., "The production of tumor necrosis factor alpha and the development of a pulmonary capillary injury following hepatic ischemia/reperfusion," <i>Transplantation</i> 49:268-72 (1990).                                 |
| 75 | Creasy, A. et al., <i>Proc. Natl. Acad. Sci. USA</i> 84:3293-3297 (1987)  |
| 76 | Dayer et al., "Purification and Characterization of Human Tumor Necrosis Factor a Inhibitor," <i>Chemical Abstracts</i> 113(38760n):454 (1990).   |
| 77 | Dembic et al., "Two human TNF receptors have similar extracellular, but distinct intracellular, domain sequences," <i>Cytokine</i> 2:231-37 (1990).   |
| 78 | Engelmann et al., "Two Tumor Necrosis Factor-binding Proteins Purified from Human Urine," <i>The Journal of Biological Chemistry</i> , Vol. 265.No.3 Issue of January 25, pp.1531-1536, 1990.   |
| 79 | Engelmann et al., "Antibodies to a soluble form of a tumor necrosis factor (TNF) receptor have TNF -like activity," <i>J. Biol. Chem.</i> 265:14497-504 (1990).   |
| 80 | Espevik et al., "Characterization of binding and biological effects of monoclonal antibodies against a human tumor necrosis factor receptor," <i>J. Exp. Med.</i> 171:415-26 (1990).  |

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC. 20231

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

|       |   |    |   |                     |          |
|-------|---|----|---|---------------------|----------|
| Sheet | 5 | of | 9 | Attorney Docket No. | 98.385-I |
|-------|---|----|---|---------------------|----------|



## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc).

|     |   |
|-----|---|
| 100 | Evans, "The steroid and thyroid hormone receptor superfamily," <i>Science</i> 240:889-95 (1988).  |
| 101 | Frohman et al., "Rapid production of full-length cDNAs from rare transcripts: amplification using a single gene-specific oligonucleotide primer," <i>Proc. Natl. Acad. Sci. U. S. A.</i> 85:8998-9002 (1988).   |
| 102 | Gatanaga et al., "Purification and characterization of an inhibitor (soluble tumor necrosis factor receptor) for tumor necrosis factor and lymphotoxin..., <i>Proc. Natl. Acad. Sci. USA</i> 87:8781-8784 (1990).   |
| 103 | Goodson et al., "Site-Directed Pegylation of Recombinant Interleukin-2 At Its Glycosylation Site," <i>BioTechnology</i> 8:343-346 (1990).   |
| 104 | Goodwin et al., "Molecular cloning and expression of the type 1 and type 2 murine receptors for tumor necrosis factor," <i>Mol. Cell. Biol.</i> 11:3020-26 (1991).  |
| 105 | Gray et al., "Cloning of human tumor necrosis factor (TNF) receptor cDNA and expression of recombinant soluble TNF-binding protein," <i>Proc. Natl. Acad. Sci. U. S. A.</i> 87:7380-84 (1990).  |
| 106 | Grizzard et al., "Affinity-labeled somatomedin-C receptors and binding proteins from the human fetus," <i>J. Clin. Endocrinol. Metab.</i> 58:535-43 (1984).   |
| 107 | Hale et al., "Cytokines and Their Receptors: From Clonal to Clinical Investigation, Demonstration of In Vitro and In Vivo Efficacy of Two Biologically Active Human Soluble TNF Receptors Expressed in E. Coli," <i>J. Cell Biochem. Suppl.</i> 15F:113(1991) |
| 108 | Hass et al., "Characterization of specific high affinity receptors for human tumor necrosis factor on mouse fibroblasts," <i>J. Biol. Chem.</i> 260:12214-18 (1985).  |
| 109 | Hatakeyama et al., "Interleukin-2 receptor beta chain gene: generation of three receptor forms by cloned human alpha and beta chain cDNA's," <i>Science</i> 244:551-56 (1989).  |
| 110 | Hauser et al., "Cytokine accumulations in CSF of multiple sclerosis patients: frequent detection of interleukin-1 and tumor necrosis factor but not interleukin-6," <i>Neurology</i> 40:1735-39 (1990).   |
| 111 | Heller et al., "Complimentary DNA cloning of a receptor for tumor necrosis factor and demonstration of a shed form of the receptor," <i>Proc. Natl. Acad. Sci. USA Vol.</i> 87, pp. 6151-6155, August 1990.   |
| 112 | Himmler et al., "Molecular cloning and expression of human and rat tumor necrosis factor receptor chain (p60) and its soluble derivative, tumor necrosis factor-binding protein," <i>DNA Cell Biol.</i> 9:705-15 (1990).                                      |
| 113 | Hofman et al., "Tumor necrosis factor identified in multiple sclerosis brain," <i>J. Exp. Med.</i> 170:607-12 (1989).   |
| 114 | Hohmann, H.P. et al., <i>J. Biol. Chem.</i> 264:14927-14934   |
| 115 | Israel et al. "Binding of Human TNF-alpha to High-Affinity Cell Surface Receptors: Effect of IFN," <i>Immunol. Lett.</i> 12:217-224(1986).  |

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC. 20231

Complete if Known

|                      |                   |
|----------------------|-------------------|
| Application No.      | 09/898,434        |
| Filing Date:         | 7-3-01            |
| First Named Inventor | Hauptmann et al., |
| Group Art Unit       |                   |
| Examiner Name        |                   |
| Attorney Docket No.  | 98,385-I          |

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

OCT 6

JUL 27 2001  
9

PATENT &amp; TRADEMARK OFFICE

## OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.).

|     |  |
|-----|--|
| 97  | Kasukabe et al., "Purification of a novel growth inhibitory factor for partially differentiated myeloid leukemic cells," <i>J. Biol. Chem.</i> 263:5431-35 (1988).   |
| 98  | Kohno et al., "A Second Tumor Necrosis Factor Receptor Gene Product Can Shed a Naturally Occurring Tumor Necrosis Factor Inhibitor," <i>Proc. Natl. Acad. Sci. USA</i> 87:8331-8335 (1990).  |
| 99  | Kull et al., "Cellular receptor for 125I-labeled tumor necrosis factor: specific binding, affinity labeling, and relationship to sensitivity," <i>Proc. Natl. Acad. Sci. U. S. A.</i> 82:5756-60 (1985).                             |
| 100 | Lantz et al., "Characterization in vitro of a human tumor necrosis factor-binding protein. A soluble form of a tumor necrosis factor receptor," <i>J. Clin. Invest.</i> 86:1396-42 (1990).   |
| 101 | Le et al., "Tumor necrosis factor and interleukin 1: cytokines with multiple overlapping biological activities," <i>Lab. Invest.</i> 56:234-48 (1987).   |
| 102 | Lee et al., "Generation of cDNA probes directed by amino acid sequence: cloning of urate oxidase," <i>Science</i> 239:1288-91 (1988).  |
| 103 | Lehmann and Droege, "Demonstration of membrane receptors for human natural and recombinant 125I-labeled tumor necrosis factor on HeLa cell clones and their role in tumor cell sensitivity," <i>Eur. J. Biochem.</i> 158:1-5 (1986). |
| 104 | Leung et al., "Growth hormone receptor and serum binding protein: purification, cloning and expression," <i>Nature</i> 330:537-43 (1987).  |
| 105 | Liao et al., "Identification of a specific interleukin 1 inhibitor in the urine of febrile patients," <i>J. Exp. Med.</i> 159:126-36 (1984).   |
| 106 | Liao et al., "Charaterization of a Human Interleukin 1 Inhibitor," <i>J. Immunol.</i> 134(6):3882-3886 (1995).   |
| 107 | Liblau et al., "Tumor Necrosis Factor-a and Disease Progreesion in Multiple Sclerosis," <i>New Engl. J. Med.</i> 326(4):272-273 (1992)   |
| 108 | Lindvall et al., "Modulation of the constitutive gene expression of the 55 kD tumor necrosis factor receptor in hematopoietic cells," <i>Biochem. Biophys. Res. Commun.</i> 172:557-63 (1990).                                       |
| 109 | Loetscher et al., "Molecular Cloning and Expression of the Human 55 kd Tumor Necrosis Factor Receptor." <i>Cell</i> , Vol. 61 351-359 April 20, 1990   |
| 110 | March et al., "Cloning, sequence and expression of two distinct human interleukin-1 complementary DNAs," <i>Nature</i> 315:641-47 (1985).  |
| 111 | Neda, Hiroshi, "Analysis of the Tumor Necrosis Factor (TNF) Receptor of Various Tumor Cells," <i>Tumor Necrosis Factor, (TNF) Receptor</i> 56(2):305-17 (1987).  |

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to compete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC. 20231

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

JUL 27 2001

PATENT &amp; TRADEMARK OFFICE

Sheet

of

9

Application No.

09/898,234

Filing Date:

7-3-01

First Named Inventor

Hauptmann et al.,

Group Art Unit

Examiner Name

Attorney Docket No.

98,385-I

JUL 30 2001

OTHER DOCUMENTS (Include Author, Title, Date, Pertinent Pages, Etc.).

|     |  |
|-----|--|
| CMA | <p>Nexl et al., "Lectin-agarose immobilization, a new method for detecting soluble membrane receptors. Application to studies with epidermal growth factor-urogastrone and transcobalamin-II," <i>J. Biol. Chem.</i> 254:8740-43 (1979).</p> <p>113 Nophar et al., "Soluble forms of tumor necrosis factor receptors (TNF-Rs). The cDNA of the type I TNF-R, cloned using amino acid sequence data of its soluble form, encodes both the cell surface and a soluble form of the receptor," <i>The EMBO J.</i> 9(10):3269-3278 (1990).</p> <p>114 Novick et al., "Soluble cytokine receptors are present in normal human urine," <i>J. Exp. Med.</i> 170:1409-14 (1989).</p> <p>115 Novick et al., "Purification of soluble cytokine receptors from normal human urine by ligand-affinity and immunoaffinity chromatography," <i>J. Chromatogr.</i> 510:331-37 (1990).</p> <p>116 Olsson et al., "Isolation and characterization of a tumor necrosis factor binding protein from urine," <i>Eur. J. Haematol.</i> 42:270-75 (1989).</p> <p>117 Peetre, C. et al., <i>Eur. J. Haematol</i> 41:414-419 (1988)</p> <p>118 Peppel et al., "A Tumor Necrosis Factor (TNF) Receptor-IgG Heavy Chain Chimeric Protein as a Bivalent Antagonist of TNF Activity," <i>J. Exp. Med.</i> 174:1483-1489 (1991).</p> |
| CMA | <p>119 Piguet et al., "Tumor necrosis factor/cachectin plays a key role in bleomycin-induced pneumopathy and fibrosis," <i>J. Exp. Med.</i> 170:655-63 (1989).</p> <p>120 Powell et al., "The Role of Lymphotoxin and TNF in Demyelinating Diseases of the CNS." <i>Tumor Necrosis Factors: The Molecules and Their Emerging Role in Medicine.</i> Pgs 355-369</p>   |
| CMA | <p>121 Rhein et al., "Another Sepsis Drug Down=Immunex-TNF Receptor," <i>Biotechnology Newswatch</i>, pg. 13 (Monday, October 4, 1993).</p>  |
| CMA | <p>122 Ruddell et al., "An Antibody to Lymphotoxin and Tumor Necrosis Factor Prevents Transfer of Experimental Allergic Encephalomyelitis," <i>J. Exp. Med.</i> 172:1193-1200 (1990).</p>  |
| CMA | <p>123 Schall, T. J. et al., <i>Cell</i> 61:361-370 (1990)</p>   |
| CMA | <p>124 Scheurich et al., "Quantification and characterization of high-affinity membrane receptors for tumor necrosis factor on human leukemic cell lines," <i>Int. J. Cancer</i> 38:127-33 (1986).</p>   |
| CMA | <p>125 Seckinger et al., "Characterization of a tumor necrosis factor alpha (TNF-alpha) inhibitor: evidence of immunological cross-reactivity with the TNF receptor," <i>Proc. Natl. Acad. Sci. U. S. A.</i> 87:5188-92 (1990).</p>  |
| CMA | <p>126 Seckinger et al., "Purification and biologic characterization of a specific tumor necrosis factor alpha inhibitor," <i>J. Biol. Chem.</i> 264:11966-73 (1989).</p>  |

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC. 20231

Complete if Known

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

O (use as many sheets as necessary)

I P E

JULY 27 2004

Application No.

09/898,234

Filing Date:

7-3-01

First Named Inventor

Hauptmann et al.,

Group Art Unit

Examiner Name

Sheet

of

9

Attorney Docket No.

98.385-I

JULY 31 2004

TRADEMARK OFFICE

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.).

|     |   |
|-----|---|
| EA  | Seckinger et al., "A Human Inhibitor of Tumor Necrosis Factor Alpha," <i>J. Exp. Med.</i> 167:1511-1516.  |
| 128 | Seckinger et al., "A Urine Inhibitor of Interleukin 1 Activity Affects Both Interleukin 1 and B But Not Tumor Necrosis Factor a," <i>J. Immunol.</i> 139(5):1541-1545(1987).  |
| 129 | Seckinger et al., "A Urine Inhibitor of Interleukin 1 Activity Affects Both Interleukin 1 and B But Not Tumor Necrosis Factor a," <i>J. Immunol.</i> 139(5):1446-1549(1987)   |
| 130 | Selmaj et al., "Prevention of Ch-r-eae with Soluble TNF Receptor P55," <i>J. Neurom.</i>  |
| 131 | Selmaj and Raine, "Anti-Tumor Necrosis Factor Therapy Abrogates Autoimmune Demyelination, <i>Annals of Neurology</i> Vol 30 No 5 November 1991.   |
| 132 | Shimuzu et al., <i>PNAS USA</i> , 80:2112-2116 (1983).  |
| 133 | Smith et al., "A Receptor for Tumor Necrosis Factor Defines an Unusual Family Cellular and Viral Proteins, <i>Reports</i> , 1019-1023.  |
| 134 | Smith et al., <i>Science</i> 248:1019-1023(1990)  |
| EA  | Socher et al., "Antibodies against amino acids 1-15 of tumor necrosis factor block its binding to cell-surface receptor," <i>Proc. Natl. Acad. Sci. U. S. A.</i> 84:8829-33 (1987).   |
| 136 | Spinas et al., "Induction of plasma inhibitors of interleukin 1 and TNF-alpha activity by endotoxin administration to normal humans," <i>Am. J. Physiol.</i> 259(5 Pt 2):R993-7 (1990).   |
| 137 | Stauber and Aggarwal, "Characterization and affinity cross-linking of receptors for human recombinant lymphotoxin (tumor necrosis factor-beta) on a human histiocytic lymphoma cell line, U-937," <i>J. Biol. Chem.</i> 264:3573-76 (1989).   |
| 138 | Stauber. G. et al., <i>J. Biol. Chem.</i> 263(35):19098-19104.  |
| 139 | Suffys et al., "Involvement of a serine protease in tumour-necrosis-factor-mediated cytotoxicity," <i>Eur. J. Biochem.</i> 178:257-65 (1988).   |
| 140 | Suggs et al., "Use of synthetic oligonucleotides as hybridization probes: isolation of cloned cDNA sequences for human beta 2-microglobulin," <i>Proc. Natl. Acad. Sci. U. S. A.</i> 78:6613-17 (1981).   |
| 141 | <i>The Cytokine Factsbook</i> pp. 244-46 (Callard, ed., Academic Press, 1994).  |
| 142 | Tracey et al., "Cachectin/tumor necrosis factor induces cachexia, anemia, and inflammation," <i>J. Exp. Med.</i> 167:1211-27 (1988).  |
| 143 | Tracey et al., "Metabolic effects of cachectin/tumor necrosis factor are modified by site of production. Cachectin/tumor necrosis factor-secreting tumor in skeletal muscle induces chronic cachexia, while implantation in brain induces predominantly acute anorexia," <i>J. Clin. Invest.</i> 86:2014-24 (1990). |

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC. 20231

Complete if Known

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT



(use as many sheets as necessary)

JUL 27 2001

|       |   |    |   |
|-------|---|----|---|
| Sheet | 9 | of | 9 |
|-------|---|----|---|

|                      |                   |
|----------------------|-------------------|
| Application No.      | 09/898,234        |
| Filing Date:         | 7-3-01            |
| First Named Inventor | Hauptmann et al.. |
| Group Art Unit       |                   |
| Examiner Name        |                   |
| Attorney Docket No.  | 98,385-I          |

## OTHER DOCUMENTS (Include Author, Title, Date, Pertinent Pages, Etc.).

|  |     |   |
|--|-----|---|
| <br><br><br><br> | 144 | Tracey et al., "Physiological responses to cachectin," <i>Tumor Necrosis Factor and Related Cytotoxins</i> pp. 88-108 (Ciba Foundation Symposium 131, Wiley, Chichester, 1987).   |
|  | 145 | Tracey et al., "Anti-Cachectin/TNF Monoclonal Antibodies Prevent Septic Shock During Lethal Bacteraemia," <i>Nature</i> 330:662-664(1987).  |
|  | 146 | Tsujimoto et al., "Physiological responses to cachectin," <i>Tumor necrosis factor and related cytotoxins</i> . Wiley, Chichester (Ciba Foundation Symposium 131), pp. 88-108 (1987).   |
|  | 147 | Unglaub et al., "Downregulation of tumor necrosis factor (TNF) sensitivity via modulation of TNF binding capacity by protein kinase C activators," <i>J. Exp. Med.</i> 166:1788-97 (1987).  |
|  | 148 | Vilcek et al., "Tumor necrosis factor: receptor binding and mitogenic action in fibroblasts," <i>J. Cell. Physiol.</i> 5:57-61 (1987).  |
|  | 149 | Vitt et al., "Biological and Structural Characterization of the Tumor Necrosis Factor Receptor on Multiple Cell Types: Relationship to Function," <i>Fed. Proc. 78th Annual Meeting of the American Society of Biological Chemists</i> 46(6):2117 (1987). |
|  | 150 | Wallach et al., "Mechanisms which take part in regulation of the response to tumor necrosis factor," <i>Lymphokine Res.</i> 8:359-63 (1989).  |
|  | 151 | Wallach, "Cell Surface and Soluble TNF Receptors, Tumor Necrosis Factor, 1992, pp 47- 57.   |
|  | 152 | Wallach et al., "Regulation of the Response to Tumor Necrosis Factor," pp. 134-47 (Bonavida et al., eds., <i>Tumor Necrosis Factor/Cachectin and Related Cytokines Int. Conf. Tumor Necrosis Factor and Related Cytotoxins</i> , Heidelberg, 1987).       |
|  | 153 | Walsh et al., "Isolation and purification of ILS, an interleukin 1 inhibitor produced by human gingival epithelial cells," <i>Clin. Exp. Immunol.</i> 68:366-74 (1987).   |
|  | 154 | Weber et al., "Production of an epidermal growth factor receptor-related protein," <i>Science</i> 224:294-97 (1984).  |
|  | 155 | Yoshie et al., "Binding and Crosslinking of <sup>125</sup> I-Labeled Recombinant Human Tumor Necrosis Factor to Cell Surface Receptors," <i>J. Biochem.</i> 100:531-541 (1986).   |
|  | 156 | Ziegler, "Tumor necrosis factor in humans," <i>N. Engl. J. Med.</i> 318:1533-35 (1988).   |

*Eileen B. O'Hara**1/21/03*

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC. 20231